Morning Market Losers
December 12, 2013 at 09:59 AM EST
ImmunoCellular Therapeutics (NYSE: IMUC ) dropped 59.85% to $1.09 after the company announced positive ICT-107 Phase II study results. Roth Capital downgraded the stock from Buy to Neutral. Synthetic Biologics (NYSE: SYN ) plummeted 22.06% to $0.99 after the company priced 11.5 million shares of common stock at $1.00. XTL
